Oportuzumab monatox for the treatment of noninvasive urothelial carcinoma in situ (CIS) previously treated with Bacillus Calmette-Guérin (BCG). Update June 2023

Rothschedl, E. and Wolf, S. (2023): Oportuzumab monatox for the treatment of noninvasive urothelial carcinoma in situ (CIS) previously treated with Bacillus Calmette-Guérin (BCG). Update June 2023. Fact Sheet Nr. 122.

[thumbnail of Fact Sheet Nr.122_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
675kB

Item Type:	Horizon Scanning of Medicines
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WJ Urogenital system > WJ 400-600 Ureter. Bladder. Urethra
Language:	English
Series Name:	Fact Sheet Nr. 122
Deposited on:	02 Feb 2023 13:13
Last Modified:	23 Jun 2023 16:04

Repository Staff Only: item control page